Abstract

SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2), A NEW APPROACH IN TYPE 2 DIABETES MELLITUS TREATMENT

Ashish Sharma*, Prof. S. K. Gupta and Dr. Sushma Srivastava

Abstract

Although antidiabetic agents have been developed to target one or more of the core defects of type 2 diabetes mellitus (T2DM), many patients do not achieve glycemic goals. Inhibition of the sodiumglucose cotransporter 2 (SGLT2) induces glycosuria, reduces glucose toxicity and improves insulin sensitivity and β-cell function. As the mechanism of action of SGLT2 inhibitors is different from other agents and completely insulin-independent, the use of these drugs might potentially be efficacious alone or in combination with any other antidiabetic drug, including insulin. SGLT2 inhibitor approved for use in adult patients with T2DM as monotherapy in patients intolerant of metformin or as adjunctive therapy in patients inadequately controlled on existing antidiabetic medications, including insulin. A literature search conducted using PubMed identified key publications related to the use of SGLT2 in the treatment of patients with diabetes mellitus. No date limits were applied. Clinical trials published to date show that SGLT2 is safe and effective as monotherapy or as an add-on to insulin or oral antidiabetic agents in patients with T2DM.

Keywords: Antidiabetic drugs, Glycosylated hemoglobin, Glycemic control, Sodiumglucose cotransporter 2 inhibitors, Type 1 diabetes mellitus, Type 2 diabetes mellitus, Weight reduction.